The compound you provided, **1-(3,4-dimethylphenyl)-2,5-dioxo-3-dipyrido[1,2-d-3',4'-f]pyrimidinecarbonitrile**, is a complex organic molecule. However, without more context, it's impossible to say definitively why it might be important for research.
Here's why:
* **Chemical Name Only:** You've only provided the chemical name, which doesn't give much information about the compound's properties or potential applications.
* **Uncommon Structure:** The structure of this molecule is quite complex, suggesting it may be a synthetic compound rather than a naturally occurring one.
* **Missing Context:** To understand its importance, we need to know:
* **What research area it's relevant to:** Is it a potential drug candidate, a material for electronics, a catalyst, or something else entirely?
* **What properties make it interesting:** Is it fluorescent, reactive, or does it interact with specific biological targets?
**How to find more information:**
1. **Search Chemical Databases:** Use databases like PubChem, ChemSpider, or SciFinder to search for the compound by its name or structure. These databases might provide information about its properties, synthesis, or potential applications.
2. **Look for Scientific Publications:** Search academic databases like PubMed or Google Scholar for publications mentioning this compound. These articles could provide context for its research significance.
3. **Contact an Expert:** If you have a specific research question, contact a chemist or researcher specializing in the relevant field for more information.
**Without further information, it's impossible to say why this specific compound is important for research. It could be a promising lead for a new drug, a component in a novel material, or simply a molecule being investigated for its unique chemical properties. **
ID Source | ID |
---|---|
PubMed CID | 9550813 |
CHEMBL ID | 1301239 |
CHEBI ID | 115588 |
Synonym |
---|
MLS000520591 , |
smr000131002 |
CHEBI:115588 |
AKOS001512856 |
CHEMBL1301239 |
CCG-143014 |
HMS2394N21 |
1-(3,4-dimethylphenyl)-2,5-diketo-dipyrido[1,2-d:3'',4''-f]pyrimidine-3-carbonitrile |
1-(3,4-dimethylphenyl)-2,5-dioxo-3-dipyrido[1,2-d:3'',4''-f]pyrimidinecarbonitrile |
bdbm52272 |
cid_9550813 |
1-(3,4-dimethylphenyl)-2,5-bis(oxidanylidene)dipyrido[1,2-d:3'',4''-f]pyrimidine-3-carbonitrile |
1-(3,4-dimethylphenyl)-2,5-dioxodipyrido[1,2-d:3'',4''-f]pyrimidine-3-carbonitrile |
1-(3,4-dimethylphenyl)-2,5-dioxo-3-dipyrido[1,2-d:3',4'-f]pyrimidinecarbonitrile |
Q27197843 |
SR-01000100490-1 |
sr-01000100490 |
1-(3,4-dimethylphenyl)-2,5-dioxo-1,5-dihydro-2h-dipyrido[1,2-a:2,3-d]pyrimidin-3-yl cyanide |
7-(3,4-dimethylphenyl)-2,6-dioxo-1,7,9-triazatricyclo[8.4.0.03,8]tetradeca-3(8),4,9,11,13-pentaene-5-carbonitrile |
Class | Description |
---|---|
pyridopyrimidine | Any organic heterobicyclic compound consisting of a pyridine ring ortho-fused at any position to a pyrimidine ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 0.6310 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 3.5481 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 0.8913 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 14.1291 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
ClpP | Bacillus subtilis | Potency | 2.5119 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
TDP1 protein | Homo sapiens (human) | Potency | 26.1011 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 12.5893 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
alpha-galactosidase | Homo sapiens (human) | Potency | 5.0119 | 4.4668 | 18.3916 | 35.4813 | AID1467 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 4.4668 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2242 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0018 | 15.6638 | 39.8107 | AID894 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 4.7394 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
snurportin-1 | Homo sapiens (human) | Potency | 4.7394 | 5.8048 | 36.1306 | 65.1308 | AID540253; AID540263 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 75.6863 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 5.0119 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
geminin | Homo sapiens (human) | Potency | 10.3225 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 4.4668 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 15.8489 | 1.9953 | 25.5327 | 50.1187 | AID624287 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 2.2387 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
karyopherin alpha 2 (RAG cohort 1, importin alpha 1), isoform CRA_b | Homo sapiens (human) | EC50 (µMol) | 1.7790 | 0.9181 | 41.9368 | 121.5000 | AID435026 |
POsterior Segregation | Caenorhabditis elegans | EC50 (µMol) | 300.0000 | 2.2010 | 47.1808 | 186.6810 | AID1964 |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | EC50 (µMol) | 55.7830 | 0.0820 | 31.0243 | 168.9080 | AID1960 |
Zinc finger protein mex-5 | Caenorhabditis elegans | EC50 (µMol) | 55.7830 | 0.0820 | 33.5679 | 168.9080 | AID1960 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |